Myeloid disorders after autoimmune disease

Area of Science:

• Hematology
• Rheumatology
• Oncology

Background:

• Autoimmune diseases (ADs) are linked to higher risks of lymphoproliferative disorders and myeloid malignancies.
• Patients with ADs, including rheumatoid arthritis and lupus, show an increased incidence of myelodysplastic syndromes and acute myeloid leukemia.
• The risk of myeloid neoplasms (MNs) in AD patients is multifactorial, influenced by disease characteristics, treatments, and genetic factors.

Purpose of the Study:

• To explore the connection between autoimmune diseases and the development of myeloid neoplasms.
• To review potential mechanisms linking ADs to MNs, including therapeutic and non-therapeutic factors.
• To summarize current knowledge on MN pathogenesis in the context of AD.

Main Methods:

• Review of existing literature on autoimmune diseases and myeloid neoplasms.
• Analysis of factors contributing to MN development in AD patients.
• Discussion of molecular mechanisms and therapeutic influences.

Main Results:

• Certain ADs are associated with a significantly higher risk of MNs.
• Therapeutic agents like azathioprine, cyclophosphamide, and mitoxantrone are linked to increased MN risk, while anti-TNF-alpha inhibitors may not share this risk.
• MNs can arise in AD patients even without prior exposure to specific therapies, suggesting complex pathogenesis.

Conclusions:

• The relationship between ADs and MNs is complex, involving genetic, environmental, and therapeutic factors.
• Further research is needed to elucidate the molecular mechanisms driving leukemogenesis in AD patients.
• Understanding these links is crucial for risk stratification and management of AD patients.